Kaushik Tarun, Yaqoob Muhammad Magdi
Barts Health NHS Trust, William Harvey Research Unit, London, UK.
Biologics. 2013;7:243-6. doi: 10.2147/BTT.S34935. Epub 2013 Nov 11.
Peginesatide is the newest erythropoietin-stimulating agent (ESA) in the quest for the ideal treatment of anemia in chronic kidney disease (CKD) patients. Reduced frequency of administration along with a possibly lower cost as a result of simpler manufacturing techniques compared with other available agents makes peginesatide a highly desirable product in the competitive ESA market. Peginesatide is noninferior to the other ESAs, and has a good safety profile in patients on hemodialysis. The higher rates of adverse cardiovascular events reported in CKD patients not on dialysis in the recent Phase III studies require further, better planned, studies. Peginesatide had to be withdrawn from the market in the US after some reports of hypersensitivity reactions to the drug. This is a setback, but the scientific advances gained as a result of this product development can be used to develop other, newer products.
培加尼肽是在寻求慢性肾病（CKD）患者贫血理想治疗方法过程中最新的促红细胞生成素刺激剂（ESA）。与其他现有药物相比，由于生产技术更简单，给药频率降低且成本可能更低，这使得培加尼肽在竞争激烈的ESA市场中成为非常受欢迎的产品。培加尼肽不劣于其他ESA，并且在血液透析患者中具有良好的安全性。最近的III期研究报告显示，未接受透析的CKD患者发生不良心血管事件的几率较高，这需要进一步开展规划更完善的研究。在有一些关于对该药物过敏反应的报告后，培加尼肽不得不从美国市场撤出。这是一个挫折，但该产品开发所取得的科学进展可用于开发其他更新的产品。
